Want to see PRQR full AI Analyst Report?
Top Page
ProQR
(NASDAQ:PRQR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(16.28% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily held back by weak financial performance—large ongoing losses and substantial negative free cash flow dominate despite strong gross margins and improving revenue. Technicals provide support with price above major moving averages and moderately positive momentum, but elevated volatility (high beta) adds risk. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Axiomer clinical validation
Clinical validation of AX-0810 demonstrates the Axiomer RNA editing platform works in humans with dose-dependent target engagement, sustained half-life and a favorable safety profile. This materially de-risks the platform, supports pipeline advancement and strengthens long-term partner and investor confidence.
Negative Factors
Cash burn
Sustained negative operating and free cash flow means the company cannot self-fund development and will need external financing to reach key mid-to-late stage milestones. Persistent cash burn increases dilution risk and compresses optionality for pursuing multiple programs simultaneously.
Read all positive and negative factors
Positive Factors
Negative Factors
Axiomer clinical validation
Clinical validation of AX-0810 demonstrates the Axiomer RNA editing platform works in humans with dose-dependent target engagement, sustained half-life and a favorable safety profile. This materially de-risks the platform, supports pipeline advancement and strengthens long-term partner and investor confidence.
Read all positive factors
ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$296.89M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)2.26
Revenue Growth19.49%
EPS Growth-4.53%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding138,087,650
10 Day Avg. Volume893,100
30 Day Avg. Volume1,361,105
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.67Price Target Upside403.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$15.71M
ProQR Business Overview & Revenue Model
Company Description
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical ...
How the Company Makes Money
ProQR is a clinical-stage biotech and, as of the most recently available public information, does not appear to have a diversified commercial product revenue base; revenue is primarily associated with collaboration and partnering arrangements rath...
ProQR Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.57M | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M |
| Gross Profit | 17.15M | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M |
| EBITDA | -29.44M | -37.04M | -24.12M | -24.10M | -56.46M | -54.95M |
| Net Income | -42.40M | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M |
Balance Sheet | ||||||
| Total Assets | 133.50M | 132.43M | 173.92M | 152.31M | 182.84M | 238.33M |
| Cash, Cash Equivalents and Short-Term Investments | 117.08M | 108.53M | 154.71M | 131.37M | 101.15M | 213.25M |
| Total Debt | 13.19M | 16.43M | 16.08M | 21.80M | 23.45M | 68.66M |
| Total Liabilities | 54.05M | 74.44M | 82.22M | 106.59M | 111.68M | 109.57M |
| Stockholders Equity | 79.44M | 57.99M | 91.70M | 45.72M | 71.58M | 129.45M |
Cash Flow | ||||||
| Free Cash Flow | -50.29M | -53.81M | -37.81M | 20.18M | -69.22M | -26.50M |
| Operating Cash Flow | -49.14M | -52.79M | -36.39M | 21.55M | -68.51M | -26.01M |
| Investing Cash Flow | -1.15M | -1.02M | -4.07M | 4.28M | -702.00K | -425.00K |
| Financing Cash Flow | 48.04M | -1.84M | 70.28M | -2.27M | -30.89M | 136.83M |
ProQR Technical Analysis
Positive
1.72
Price Trends
1.75
Positive
1.69
Positive
1.79
Positive
Market Momentum
0.07
Negative
67.33
Neutral
77.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 1.72 is below the 20-day moving average (MA) of 1.84, below the 50-day MA of 1.75, and below the 200-day MA of 1.79, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 67.33 is Neutral, neither overbought nor oversold. The STOCH value of 77.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $423.48M | -2.69 | -64.25% | ― | ― | -29.71% | |
56 Neutral | $569.93M | -11.64 | -16.59% | ― | 67.01% | 40.54% | |
52 Neutral | $296.89M | -4.80 | -68.44% | ― | 19.49% | -4.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $164.26M | -4.76 | -74.36% | ― | 35.89% | 58.70% | |
41 Neutral | $57.13M | -1.68 | -300.90% | ― | 0.99% | -3014.75% |
* Healthcare Sector Average
PRQR
ProQR
2.22
0.08
3.74%
CDXS
Codexis
1.60
-1.22
-43.26%
HRTX
Heron Therapeutics
0.31
-0.99
-75.85%
TLSA
Tiziana Life Sciences
1.07
-0.74
-40.88%
AVIR
Atea Pharmaceuticals
5.59
2.09
59.71%
OABI
OmniAb
4.19
2.36
128.96%
ProQR Corporate Events
ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation
Aug 13, 2026
ProQR reported second-quarter 2026 results on August 13, 2026, highlighting its first clinical validation of the Axiomer platform via NTCP modulation with AX-0810 in a Phase 1 study in healthy volunteers. The company also emphasized its evolution ...
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results
Aug 13, 2026
On August 13, 2026, ProQR Therapeutics filed a Form 6-K and issued a press release reporting unaudited results for the three and six months ended June 30, 2026, along with a business update. The filing shows higher revenue versus the prior year pe...
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement
Jun 26, 2026
On June 25, 2026, ProQR Therapeutics priced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, raising gross proceeds of about $50 million, with closing expected on June 26, 2026. After underwriting discou...
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform
Jun 25, 2026
On June 25, 2026, ProQR reported positive interim Phase 1 data for AX-0810, its first Axiomer RNA editing oligonucleotide targeting the NTCP transporter, in healthy volunteers. The study showed dose-dependent NTCP target engagement across predefin...
ProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGM
Jun 2, 2026
On June 2, 2026, ProQR Therapeutics N.V. held its annual general meeting of shareholders in Amsterdam, where investors approved the 2025 annual accounts and released the board from liability for its 2025 performance. Shareholders also appointed Dr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.